Related Experiment Videos
[Primary hyperoxaluria type 1 detected by liver biopsy]
E H Nielsen1, M T Severinsen, P Jensen
1Medicinsk afdeling C, Aalborg Sygehus.
Ugeskrift for Laeger
|April 15, 1999
Summary
Primary hyperoxaluria type 1 (PH1) results from alanine:glyoxylate aminotransferase (AGT) deficiency. A 42-year-old man with PH1 showed reduced AGT activity and responded to pyridoxine treatment, suggesting its therapeutic potential.
Area of Science:
- Biochemistry
- Genetics
- Nephrology
Background:
- Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder caused by a deficiency in the liver-specific enzyme alanine:glyoxylate aminotransferase (AGT).
- The condition typically presents early with progressive kidney failure and systemic oxalosis due to oxalate accumulation.
- Understanding the genetic basis and enzyme activity is crucial for diagnosis and management.
Observation:
- A case study of a 42-year-old male patient diagnosed with PH1 is presented.
- Diagnostic investigations included a liver biopsy and DNA analysis.
- The patient exhibited reduced AGT activity and was found to be homozygous for the C154T polymorphism and the G630A point mutation.
Findings:
- Liver biopsy and DNA analysis confirmed reduced AGT activity in the affected patient.
- Genetic analysis revealed homozygosity for specific mutations (C154T and G630A) linked to PH1.
- The patient demonstrated a positive clinical response to pyridoxine (Vitamin B6) treatment.
Implications:
- The findings suggest that pyridoxine treatment may be a viable therapeutic option for PH1 patients with specific genetic profiles.
- A diagnostic liver biopsy is recommended for suspected cases of PH1 to confirm reduced AGT activity.
- Early diagnosis and targeted treatment, such as pyridoxine therapy, can potentially alter the disease course and manage systemic oxalosis and renal failure.